Regulus Raises $20M from Alnylam, Isis
Regulus Therapeutics said this week that it has received $20 million in Series A preferred equity funding from its two parent companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: gene flow between ancient chimpanzees and bonobos, and more.
A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.
Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.
In Nature this week: genetic history of HIV in the US, and more.